TECNIMUSA S.L.

Their core work

TECNIMUSA is a Spanish technology SME specializing in wearable robotic exoskeletons designed to restore autonomous movement to people with paraplegia. Their core product is the HUMEXE system — a human exoskeleton that enables spinal cord injury patients to walk independently. They progressed from concept validation to full product development through the European SME Instrument program, demonstrating both technical maturity and commercial ambition. Their work sits at the intersection of medical robotics, rehabilitation engineering, and embedded movement control systems.

What they specialise in

How they've shifted over time

TECNIMUSA entered H2020 in 2015 with a feasibility study for their exoskeleton concept under the SME Instrument Phase 1 — at that stage the project data carries no detailed keywords, suggesting an early-stage technology definition. By 2017, having passed the Phase 2 selection, the focus sharpened into three precise technical pillars: exoskeleton hardware, paraplegia as the target condition, and autonomous movement control as the differentiating capability. There is no pivot or sector shift — this is a company that picked one hard problem and deepened its commitment to solving it over eight years.

TECNIMUSA is on a single-product deepening trajectory — from concept validation through full development — suggesting they are approaching or have reached a commercial product stage that would make them a potential technology licensor, clinical trial partner, or acquisition target in the assistive robotics space.

How they like to work

TECNIMUSA has acted exclusively as project coordinator across both H2020 projects, running solo under the SME Instrument mechanism — a program designed for individual companies rather than consortia. As a result, they show zero recorded consortium partners, which reflects the funding instrument rather than an isolationist strategy. Any potential collaborator should expect to engage with a founder-led, product-focused team that drives its own agenda rather than fitting into someone else's consortium structure.

TECNIMUSA has no recorded consortium partners in the H2020 database, as both projects were executed under the solo SME Instrument scheme. Their collaboration network, if any, exists outside the EU project record — likely through clinical partners, hospitals, or rehabilitation centers not captured here.

What sets them apart

TECNIMUSA is one of very few Spanish SMEs that successfully completed both phases of the SME Instrument for a medical exoskeleton product — a signal that their technology passed rigorous EU-level commercial and technical evaluation twice. Unlike university spinouts developing exoskeleton research platforms, TECNIMUSA is explicitly targeting a commercial medical device for paraplegic patients, which positions them closer to the clinical market than most academic robotics teams. For a consortium needing an end-user-oriented medical robotics partner with a real product, rather than a research prototype, they are an unusual find at SME scale.

Highlights from their portfolio

• HUMEXE (Phase 2)
  The largest project by far at €1.34M and running six years (2017–2023), this Phase 2 SME Instrument award represents a full commercial development cycle for a paraplegic exoskeleton — one of the longer and better-funded single-company medical robotics projects in H2020.
• HUMEXE (Phase 1)
  The successful Phase 1 feasibility study (2015–2016) that unlocked Phase 2 funding demonstrates the technology concept was validated against EU commercial viability criteria, not just scientific merit.